Core Insights - Merge Labs, co-founded by OpenAI CEO Sam Altman, has raised $252 million in funding, with OpenAI as the largest investor, aiming to develop brain-computer interface devices to seamlessly connect humans with AI [1] - The funding round was led by Bain Capital, with other investors including Gabe Newell, co-founder of Valve Corporation [1] - Merge plans to initially focus on medical applications before expanding to consumer products, although it has not disclosed its valuation [1] Company Overview - Merge aims to develop non-invasive brain-computer interface devices, differentiating itself from competitors like Neuralink, which focuses on invasive implants [2] - The company is positioned as a research lab to tackle complex scientific and engineering challenges associated with high-bandwidth devices that can process large amounts of data [2] - Merge currently has fewer than 50 employees and is planning to continue hiring, without a designated president or CEO [5] Competitive Landscape - The launch of Merge intensifies the competition between Altman and Elon Musk, who were once close business partners and co-founders of OpenAI [3] - Musk founded Neuralink in 2016 to develop implantable devices aimed at enhancing human capabilities and preventing obsolescence in the age of AI [4] Industry Dynamics - The brain-computer interface sector has seen rapid growth, with over $2 billion in funding in the U.S., driven by advancements in AI that provide the necessary computational power for brain implants [5] - Companies are exploring non-surgical products, such as external headsets, which are perceived as more attractive to consumers [5]

Group 1 - The medical device sector is experiencing volatility, with the medical device ETF (159873) achieving a trading volume of 48.6 million yuan and a turnover rate exceeding 26%, leading in its category [1] - The medical device ETF has seen a net inflow of over 60 million yuan in the past 10 days, with a net subscription of 57 million units in the latest session [1] - TSMC's fourth-quarter earnings report exceeded expectations, with a net profit growth of 35% year-on-year, signaling a sustained AI boom [1] Group 2 - The medical device ETF (159873) tracks the healthcare index and has a high concentration of brain-computer interface stocks, accounting for over 17% of its holdings [2] - The ETF includes significant exposure to innovative domestic companies and is expected to undergo a comprehensive valuation recovery due to accelerated exports and new technologies [2] - The chip ETF Tianhong (159310) tracks the semiconductor industry index and benefits directly from domestic substitution and technological breakthroughs in the semiconductor sector [2]

记者丨陶力 倪雨晴 彭新 孔海丽 董静怡 骆轶琪 编辑丨骆一帆 科技的迭代速度，正愈发超越人们想象。 2025年，人工智能、量子计算、聚变能源、航天工程等关键领域，均迎来突破性进展，中国 与美国在核心赛道的引领与竞争，推动全球科技格局发生深刻变革。从开源AI模型打破算力 垄断到"人造太阳"刷新能源探索纪录，从量子计算逐步突破到商业航天技术成熟，一系列重 大科技事件不仅重塑了产业生态，也改写了技术发展的底层逻辑。 随着技术积累的持续深化与应用场景的不断拓展， 2026年成为科技从"实验室走向产业化"的 关键一年 ，AI与物理世界的深度融合、脑机接口探索商业化、低空经济的规模化发展等趋 势，将进一步推动科技与民生、产业的深度绑定，开启新一轮全球科技革命与产业变革。 21世纪经济报道科技团队在采访行业专家和资深从业人员的基础上，经过深入讨论和研究， 系统梳理出了2025年全球重大科技事件，观察和透视2026年行业发展新趋势，力图呈现科技 浪潮下的产业变革与未来图景。 2 0 2 5年全球科技重大事件回顾 1.DeepSeek引领全球开源AI模型 2025年春节期间，DeepSeek火爆出圈，迅速在全球应用市场霸榜， ...

Summary of Medical Surgical Robots Conference Call Industry Overview - The medical surgical robot market in China is in its early stages, with a market size of less than 100 billion RMB, but is experiencing rapid growth due to improvements in policies, payment systems, and hospital demand [1][2][5] - The laparoscopic surgical robot segment is a major focus, with a global market size of approximately 10.2 billion USD and a compound annual growth rate (CAGR) of 17%. The domestic market size is around 4 billion RMB, with a CAGR of 15% [1][3] Key Companies and Market Dynamics - Major players in the laparoscopic surgical robot market include Intuitive Surgical's Da Vinci system, which has a penetration rate in the U.S. of 5,800 units and nearly 10,000 globally, while domestic installations are below 500, indicating significant room for growth [3] - In the orthopedic surgical robot sector, Tianzhihang is a leading domestic company with a high market share, focusing on trauma, spine, and joint surgeries. The market is expected to grow rapidly due to improved policies and clinical demand [1][2][3] Technological Advancements - Significant advancements in surgical robot technology have been made, including breakthroughs in hardware and software systems. The integration of brain-machine interfaces is becoming essential, driving the industry towards high mobility and high-speed automation, significantly enhancing efficiency [4] - The Da Vinci system has achieved a mature status with multi-port and single-port systems, completing over a million cases in the U.S. and achieving a penetration rate of 22% [4] Policy Impact - Recent policy changes have clarified service operation projects and pricing mechanisms, promoting rationalization of service prices and enhancing hospitals' willingness to purchase and use surgical robots. This is expected to accelerate industry development [5] - The payment system is gradually improving, with more hospitals adopting relevant fee structures, which will enhance effective charging capabilities at the terminal level [5] Market Trends and Future Outlook - The demand for surgical robots is strong, particularly for cardiovascular and neurosurgery applications, with companies like Huake Precision capturing significant market shares [8] - Domestic companies are competing with imported brands and are moving towards multi-functional platforms. Tianzhihang has developed a technology platform that covers multiple surgical areas [7] - The overseas market for domestic companies is approaching 10 billion RMB, indicating potential for significant growth in international markets [7] Notable Companies in the Market - Tianzhihang is recognized as a leading orthopedic surgical robot company, with products covering spine, trauma, and joint surgeries, and has received EU CE certification [9][10] - MicroPort Medical is one of the strongest domestic companies, with a product range that includes laparoscopic and orthopedic robots, and has received significant orders [11] - Jingfeng Medical focuses on multi-port and single-port laparoscopic robots, with strong sales performance and a growing presence in international markets [12] - Sanyou Medical is developing a spine surgical robot expected to be launched in 2026, enhancing safety in complex procedures [13] Conclusion - The medical surgical robot industry in China is poised for rapid growth driven by technological advancements, supportive policies, and increasing clinical demand. Domestic companies are making significant strides in both the local and international markets, positioning themselves competitively against established global brands [1][2][5][7][8]

Summary of Aipeng Medical Conference Call Company Overview - Aipeng Medical focuses on the commercialization of non-invasive brain-computer interfaces, particularly in intraoperative anesthesia monitoring, achieving over 10 million yuan in revenue. However, progress has been hindered by medical cost control measures, prompting the company to actively explore new applications [2][6]. Key Points and Arguments Revenue Projections - The company anticipates that new applications targeting treatment systems for refractory insomnia and multimodal ADHD could generate tens of millions of yuan in revenue by 2026, with 2027 potentially marking a turning point in performance, contingent on a solid commercialization foundation in hospitals [2][6]. Product Offerings and Market Penetration - Aipeng Medical's perioperative brain state monitoring product is available in approximately 20 provinces, charging around 300 yuan per session, and is not covered by medical insurance. Similar models are used for the refractory insomnia and pediatric ADHD treatment systems [2][7]. - The intraoperative anesthesia monitoring product has been adopted in over 100 hospitals, with a target of exceeding 200 by 2026. The refractory insomnia treatment system has partnered with two hospitals, while the pediatric ADHD treatment aims to cover the top 100 pediatric clinics in China [2][8]. Research and Development - A semi-invasive epilepsy warning product is in the prototype research phase, expected to have a prototype by the end of 2026 and enter animal clinical trials in 2027, collaborating with research institutions [2][9]. Strategic Partnerships - Aipeng Medical holds a stake in Ruishen An, a company focused on implantable neurostimulation devices, which has received 15 product certifications and is projected to exceed 100 million yuan in revenue by 2025, ranking among the top three to four in the domestic neurostimulation field [4][11]. Competitive Landscape - The company differentiates its strategy by focusing on pain, anesthesia, sleep, and attention disorders, contrasting with competitors that emphasize rehabilitation or motor imagery. Aipeng Medical plans to accumulate clinical validation through hospital channels before gradually promoting products to the consumer market [5][13]. - Non-invasive and semi-invasive brain-computer interface technologies each have their advantages. Non-invasive products are expected to commercialize rapidly within 2-3 years, while semi-invasive and fully implanted devices will become significant as technology advances and costs decrease [5][14]. Future Outlook - Aipeng Medical aims to enhance its stake in Ruishen An through share transfers, with expectations of results in the first half of the year, despite lengthy processes for state-owned capital exits [4][12]. - The company expects gradual recovery and stable growth in its pain management business by 2026, despite initial impacts from centralized procurement policies. The nasal care business faces challenges but is anticipated to rebound as the economy improves [15]. Additional Important Information - The company’s non-invasive products are currently not covered by medical insurance, which affects their market penetration and pricing strategy [7]. - Aipeng Medical's approach emphasizes building strong clinical data and partnerships with hospitals to establish a competitive edge in the medical field [14].

每经记者丨肖鸿月 每经编辑丨叶峰 ｜2026年1月16日星期五｜ NO.1 嘉实基金17只产品同日公告分红 公募排排网最新数据显示，截至1月13日，今年以来已有145家公募机构参与A股上市公司调研活动，覆 盖26个申万一级行业中的154只个股，累计调研次数高达999次。 从年初公募机构的调研来看，计算机、电子、医药生物等行业成为热门调研领域，其中，数字人民币、 人工智能、机器人、脑机接口、商业航天等前沿领域最受关注。 1月14日，嘉实基金一次性发布17份基金收益分配公告，包含主动权益、债券、被动指数等多类产品。 具体来看，主动权益类基金中，嘉实主题精选、嘉实增长混合、嘉实量化阿尔法等多只产品公告分红。 其中，嘉实主题精选在2025年已实施4次分红。自成立以来累计分红总额超100亿元。 NO.2 有"老基金"触发比例配售 1月14日，中欧基金发布公告，截至2026年1月12日，中欧小盘成长混合的基金资产净值已超过规模控制 上限20亿元，根据规模控制公告的规定，管理人将对2026年1月12日当日的有效申购申请采用比例确认 的原则给予部分确认，确认比例为47.843581%。 一般来说，比例配售通常发生在新发基金首 ...

Core Insights - Merge Labs, founded by OpenAI CEO Altman, has completed a $250 million seed funding round with a valuation of $850 million [1] - OpenAI is the largest investor in this funding round and will collaborate with Merge Labs to develop scientific foundational models and advanced tools [1] Funding Details - The seed funding round raised a total of $250 million [1] - Merge Labs' valuation at the time of funding was $850 million [1] Company Vision - Merge Labs aims to utilize non-invasive methods, such as ultrasound, to transmit and receive information rather than invasive brain-machine technologies [1] - The collaboration with OpenAI is intended to "accelerate progress" in the development of innovative technologies [1]

Core Viewpoint - The article highlights the strong performance of 37 Interactive Entertainment, driven by its strategic investments in AI and technology, positioning it as a leader in the gaming industry and beyond [1][2]. Group 1: AI and Gaming Sector - The rise of AI applications has made gaming one of the most mature fields for AI technology deployment, attracting significant investor interest and accelerating market trends [1]. - 37 Interactive Entertainment has developed its own AI model, "Xiao Qi," which has been widely applied across various business functions, enhancing its operational capabilities [1]. Group 2: Investment Strategy and Value Creation - 37 Interactive Entertainment has constructed a value logic that transcends traditional gaming companies through strategic technology investments, marking a critical moment for value realization [2]. - The company has invested in several promising firms, including Zhipu, Lijing Innovation, and Qiangnao Technology, which are gaining market attention and aligning with trends in AI, fruit supply chains, and brain-computer interfaces [2][6]. Group 3: Systematic Investment Approach - The company’s investment strategy is comprehensive, covering the entire value chain from foundational computing power to upper-level applications, which strengthens its market position [6]. - 37 Interactive Entertainment's investments span various sectors, including AI, quantum computing, and biomanufacturing, positioning it for future growth and innovation [6][7]. Group 4: Ecosystem Empowerment and Business Synergy - The company actively explores ecosystem empowerment, enhancing the development of its industrial ecosystem while reinforcing its business synergies [9][10]. - The investment in Qiangnao Technology exemplifies its strategy, as this company is a leading player in the brain-computer interface sector, promising significant collaborative opportunities [11][12]. Group 5: Long-term Growth and Value Reassessment - The strong performance of 37 Interactive Entertainment is not merely a short-term phenomenon but reflects the maturation of its investment ecosystem, leading to new growth paradigms and value reassessment [14]. - The company’s extensive user base and rich content offerings provide a fertile ground for innovative product development and market testing, fostering a robust partnership with its investments [14].

Core Viewpoint - The article highlights the strong performance of 37 Interactive Entertainment, driven by its strategic investments in AI and technology, positioning it as a leader in the gaming industry and beyond [1][2]. Group 1: AI and Gaming Sector - The rise of AI applications has made gaming one of the most mature fields for AI technology deployment, attracting significant investor interest and accelerating market trends [1]. - 37 Interactive Entertainment has developed its own AI model, "Xiao Qi," which has been widely applied across various business functions, enhancing its operational capabilities [1]. Group 2: Investment Strategy and Value Creation - 37 Interactive Entertainment has constructed a value logic that transcends traditional gaming companies through strategic technology investments, marking a critical moment for value realization [2]. - The company has invested in several promising firms, including Zhipu, Lijing Innovation, and Qiangnao Technology, which are gaining market attention and aligning with trends in AI, fruit supply chains, and brain-computer interfaces [2][6]. Group 3: Systematic Investment Approach - The company has a broad investment portfolio that spans from foundational computing power to upper-level applications, creating a comprehensive industry chain [6]. - Its investments cover various sectors, including AI, semiconductors, and quantum computing, establishing a robust infrastructure for future growth [6][7]. Group 4: Ecosystem Empowerment and Business Synergy - 37 Interactive Entertainment's investment narrative emphasizes not only precise positioning in core technology sectors but also the exploration of ecosystem empowerment to drive industry development [9]. - The investment in Qiangnao Technology exemplifies the company's strategy, aiming to leverage brain-computer interface technology in entertainment and education, fostering significant business synergies [11][13]. Group 5: Long-term Growth and Value Reassessment - The strong performance of 37 Interactive Entertainment is not merely a short-term phenomenon but reflects the maturation of its investment ecosystem, leading to new growth paradigms and value reassessment opportunities [14]. - The company's extensive user base and rich content will provide practical scenarios for testing and developing innovative products and services, reinforcing its position in the evolving landscape of the entertainment industry [14].

Core Viewpoint - The "14th Five-Year Plan" emphasizes the importance of consolidating and strengthening the foundation of the real economy as a strategic task, highlighting its critical role in China's modernization efforts [1]. Group 1: Modern Industrial System - Building a modern industrial system is a strategic choice to strengthen the foundation of the real economy and is essential for promoting high-quality development [2]. - The focus should be on intelligent, green, and integrated development, promoting deep integration of technological and industrial innovation [2]. - Traditional industries need optimization and enhancement, while emerging industries should focus on cultivation and growth in sectors like new energy and aerospace [2]. Group 2: Manufacturing Sector - The manufacturing sector is fundamental to national strength and the core of the modern industrial system, with China's manufacturing value added accounting for nearly 30% of the global total [3]. - China has maintained its position as the world's largest manufacturer for 15 consecutive years, producing the majority of 504 major industrial products globally [3]. - The goal is to strengthen and optimize the manufacturing sector, ensuring it remains a backbone of the modern industrial system [3]. Group 3: Service Industry - The modern service industry is a crucial support for the modern industrial system, but it faces structural and systemic challenges [3]. - There is a need to promote high-quality development in the service sector, enhancing the integration of productive services with manufacturing [3]. - The focus should be on improving the quality and diversity of life services while advancing the digitalization of the service industry [3]. Group 4: Infrastructure Development - Infrastructure is essential for industrial development and must be optimized to support the real economy [4]. - A modern infrastructure system should leverage China's large market and existing facilities, focusing on new infrastructure construction and the digital transformation of traditional infrastructure [4]. - The goal is to enhance the resilience and adaptability of infrastructure to support China's modernization efforts [4].